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ABSTRACT: In sarcoidosis, pulmonary and general symptoms often do not cor­
relate with radiographic stage and routinely performed lung function tests. Asymp­
tomatic muscle involvement in sarcoidosis is common, but little is known about 
respiratory muscle involvement The aim of this study was to investigate any rela­
tionships between persistent complaints and/or quality of life and respiratory mus­
cle strength and endurance, respectively.
Measurements of maximal inspiratory and expiratory mouth pressures (Pi,mux 
and ¿>E,inax), respiratory muscle endurance and routine lung function were made 
in 18 patients with sarcoidosis. To assess health status and quality of life, patients 
completed the Sickness Impact Profile (SIP),
Respiratory muscle strength and endurance time were lower in the patient group 
than in a group of healthy controls (p=0.05). Compared to a general population, 
the patients with sarcoidosis were found to he limited in physical and psycho­
social functioning. The respiratory muscle endurance time correlated with the SIP 
subscales "mobility" (r«-0.56; p<0.01), and "body care and movement" (r=-0.79; 
p<0.001). The total lung capacity (TLC), inspiratory vital capacity (IVC) and for­
ced expiratory volume in one second (FEVi) were normal in all subjects.
In conclusion, patients with sarcoidosis and normal lung function showed 
reduced respiratory muscle strength and endurance time. Correlations were found 
between these indices and both symptoms and certain Sickness Impact Profile 
domains. Therefore, we suggest inclusion of measurements of respiratory muscle 
strength in the assessment and follow-up of patients with sarcoidosis.
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Sarcoidosis is a multisystem disorder, which can affect 
essentially every organ of the body [1]. The parts of 
the body most frequently involved are the lungs, lymph 
nodes, skin, eyes, muscles, heart and joints, and, there­
fore, symptoms vary considerably. In sarcoidosis, dise­
ase activity does not necessarily indicate a progressive 
or fatal course [2]. Even though the active disease often 
subsides spontaneously, an indication of activity is nec­
essary in order to monitor the course of the disease and 
to guide treatment, should the clinical situation justify 
it [2, 3], Whilst there is no single test that accurately 
reflects the progression of sarcoidosis, clinical exami­
nation, chest radiography and lung function tests are used 
to evaluate and monitor the disease process. Techniques 
useful in assessing the extent and severity of granuloma­
tous inflammation and fibrosis are: 1) serum markers, 
including serum angiotensin converting enzyme (sACE); 
2) 67Ga scan; 3) bronchoalveolar lavage (BAL); and 4) 
high resolution computed tomography (HRCT) [2, 4]. 
When indicators of disease activity, such as radiogra­
phic abnormalities, lung function impairment and s ACE, 
return to normal, nonspecific symptoms, such as fatigue 
and reduced exercise tolerance, may persist.
In a previous study, we found that the quality of life 
measured by the Sickness Impact Profile (SIP) was re­
lated to the perception of complaints, but not to dise­
ase activity as conventionally assessed [5], The SIP is 
a generic health status instrument, which is intended to 
measure the impact of sickness rather than to objec­
tively measure the presence of disease [6]. It is an indi­
vidual's own experience of illness perceived through its 
effect on daily activities, feelings and attitudes [7].
Asymptomatic granulomatous muscle involvement in 
sarcoidosis has been reported with a prevalence of 50- 
80% [8], whereas symptomatic muscle involvement is 
much less common (range 1.4-2.3%) [9]. The sympto­
matic involvement that has been described varies from 
a palpable nodular type to an acute myositis, and a chro­
nic myopathic type [9-12]. Usually, patients present 
with pain, weakness and muscle atrophy [13]. Little is 
known, however, about the frequency of respiratory 
muscle involvement [14].
The aim of this study was to investigate whether there 
is a relationship between persistent complaints or qual­
ity of life disturbance and respiratory muscle function 
in a population of patients with sarcoidosis. Therefore,
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the relationships between respiratory muscle strength, 




Eighteen out-patients suffering from sarcoidosis, who 
attended the Academic Hospital Nijmegen, were studied. 
The diagnosis of sarcoidosis was based on consistent 
clinical features, together with biopsy-proven noncaseat- 
ing epitheloid cell granuloma. The clinical symptoms 
of the respective patients varied from none (sarcoidosis 
detected on routine chest radiography) to more or less 
severe respiratory symptoms or erythema nodosum and 
arthralgia (i.e. Lofgren's syndrome). None of the par­
ticipating subjects had any significant medical history 
that might have influenced quality of life. Patients with 
significant co-morbidity were excluded.
A control group (n=18), comprising healthy employ­
ees of the Academic Hospital Nijmegen matched for age 
and gender, were used as reference for the lung function 
tests, respiratory muscle strength and endurance time, as 
well as peripheral muscle strength. A control group 
comprising 594 subjects from a general Dutch popula­
tion (mean age 43 yrs, range 18-75 yrs; 267 males (45%) 
and 327 females (55%)) were used as reference to com­
pare the SIP measurements [15].
Study design
Initially, 26 patients with sarcoidosis were contact­
ed. Eight declined for various personal reasons. Eight­
een patients agreed to participate after giving informed 
consent. The questionnaires were completed under 
supervision of a study assistant, to avoid missing data 
or misunderstanding. In addition, the patients were 
asked about their smoking history and whether they had 
any of the following complaints: fatigue, dyspnoea, cough, 
arthralgia, or erythema nodosum.
At the time the study was performed, seven of the 
patients still had symptoms, most notably fatigue. Ele­
ven of the 18 patients had not taken corticosteroids dur­
ing the previous 3 months. The other seven patients 
were taking corticosteroids during the 3 months prior 
to the study, with an average prednisone dose of 5.7 
mg‘day_1. Five of these seven patients still had symp­
toms. The mean ( ± s d ) sACE level was 16.8±5.9 U L 1 
(reference value <20 U*!/1)* The radiographic stage var­
ied from 0 to III: four patients had stage 0, two stage
I, 10 stage II, and two stage III appearances. Demograp­
hic and clinical characteristics of the patients and the 
control group are summarized in table 1.
Table 1. -  Characteristics of patients with sarcoidosis 
and control subjects
V ariable Sarcoidosis patients Control subjects
(n=18) (n=18)
Age yrs 43 (11) 41 (11)
Gender male/female 11/7 8/10
Smoking yes/no 1/17 9/9
Complaints yes/no 7/11
Time since diagnosis yrs 7.2 (7.1) -
Data are expressed as absolute number or mean, and sd in 
parenthesis.
Lung function tests
Lung function measurements included forced expira­
tory volume in one second (FEVi), inspiratory vital 
capacity (IYC) measured with a pneumotachograph, 
and total lung capacity (TLC) measured using a body 
plethysmograph (Compactbody; Jaeger, Wurzburg, Ger­
many). The best of three efforts was selected. All volu­
mes were expressed as percentages of the reference values 
[16].
The transfer factor of the lung for carbon monoxide 
(7L,CO) was measured by the single-breath method (Mas- 
terlab; Jaeger, Wurzburg, Germany). In order to compare 
the 7L,co level with the quality of life scores, the values 
were classified into four ranges: 1) normal (>80%); 2) 
mild decrease (60-80%); 3) moderate decrease (40-60%); 
and 4) severe decrease (<40% of predicted), according 
to the American Medical Association classes.
Respiratory muscle strength and respiratory muscle 
endurance
Inspiratory and expiratory muscle strength were ass­
essed by measuring maximal respiratory mouth pres­
sures using the method of B lack  and H yatt [17]. Maximal 
inspiratory mouth pressure (Pi,max) was measured at 
residual volume (RV), whilst maximal expiratory mouth 
pressure (PE,max) was measured at total lung capacity 
(TLC). The equipment used was a pressure transducer 
(model MP 45-30; Validyne Engineering Corp., North- 
ridge CA, USA). All signals were recorded on a strip 
chart (type BD 31; Kipp & Zonen, Delft, The Netherlands). 
A needle was placed in the proximal end of the mouth­
piece to ensure that efforts were performed with open 
glottis. At least five manoeuvres were performed, until 
the three highest values were within 5% of each other. 
All subjects were seated in the upright position and were 
wearing a noseclip while performing the tests, and the 
same instructions were given to each subject by one 
investigator. Values are expressed in absolute terms and 
as percentages of predicted values according to WrLSON 
et a l [18].
Respiratory muscle endurance was assessed by mea­
suring the endurance time using a modified threshold 
loading device as designed by N ickerson  and K eens 
[19]. This device has an inspiratory valve, which can be 
occluded by a weighted plunger. The plunger can be ad­
justed externally so that patients must generate enough 
inspiratory pressure to lift the inspiratory valve and allow 
inspiratory flow. Expiration can be performed without 
any resistance. The threshold loading device was first 
tested and validated in healthy subjects before use. 
There was a very close relationship between the inspira­
tory pressure (Pi) generated and external weight (W)
(Pl=-(0.201126xW + 7.4659); r=0.999, p<0.001; Pi in
cmH20, W in g). The respiratory muscle endurance time 
was defined as the maximal time (in seconds) during 
which a subject could sustain breathing against an inspi­
ratory pressure load equal to 70% of his/her individual 
Pi,max [20], All subjects first warmed up by breathing 
against an inspiratory pressure load equal to 15% of 
their Pi,max during 2 min. Next they were presented with 
their individual test load and instructed to breathe for
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as long as they could, until they became so tired they 
could not continue or until they were unable to get enough 
air. The test was terminated if the respiratory muscle 
endurance time exceeded 15 min. During the test, the in- 
spiratory pressure was recorded constantly on the strip 
chart as described.
Peripheral muscle strength
Quadriceps force was measured on the nondominant 
side with the subject sitting, both hip and knee in 90° 
flexion, the ankle connected to measuring-equipment 
based on strain gauges. A nonstretching-band was placed 
around the hip to prevent the subject from lifting up 
whilst pulling away the lower leg. The force of the hand 
muscles was also measured on the nondominant side 
with the subject sitting, the forearm and hand in a direct 
line with each other and resting on a table, and the fin­
gers enclosing two wooden handles connected to the 
measuring equipment based on strain gauges. In both 
tests, at least three isometric contractions were perform­
ed until the differences were not more than 5%. Bet­
ween each effort there was an interval of 1 min. Values 
are expressed as kilogram force (kgf).
Health status questionnaire
Health status and quality of life were assessed with 
the SIP (Dutch version) [15, 21], The SIP was design­
ed to assess sickness-related behavioural dysfunction. It 
provides summary scores for physical, psychosocial, 
and overall behavioural dysfunction, as well as sepa­
rate scores for 12 categories of activity. The scores are 
expressed as percentages of the maximal possible score 
of dysfunction in that particular category or set of cat­
egories [22]. The scores range between 0 and 100. The 
higher the scores, the stronger the impact of the disease 
on the individual’s life.
Statistical analysis
The data of the control subjects and patients were 
compared using Student's t-test for binomial values and 
Chi-squared test for ordinal values. Differences in per­
sonal characteristics were assessed using Chi-squared 
tests for categorical data and Student’s t-tests for con­
tinuous data. Correlation among variables was assessed 
by single regression analysis. Because of the large num­
ber of correlations examined, a p-value of less than 0.01 
was considered to be statistically significant. All ana­
lyses were performed using the Statistical Package for 
Social Sciences (SSPS).
Results
Tables 2 and 3 summarize the results of the SIP scor­
es, and the lung function tests, respiratory and periphe­
ral muscle strength assessments, respectively.
The total SIP scores for the patient group were sig­
nificantly higher compared with the control subjects. In
Table 2. -  Average Sickness Impact Profile (SIP) 








Alertness behaviour 9.9 (20.7)** 4.6 (12.4)
Ambulation 4.1 (8.4) 3,0 (7.8)
Body care and movement 1.7 (3.8) 1.9 (5.0)
Communication 2.5 (4.3) 1.1 (4.5)
Eating 1.1 (3.4) 1.0 (3.2)
Emotional behaviour 5.7 (12.3) 4.0 (10.0)
Home management 6.9 (11.3)** 4.8 (11-8)
Mobility 2.9 (5.6) 2.4 (7.6)
Recreation and pastimes 10.5 (15.8)** 7.6 (14.1)
Sleep and rest 14.3 (16.9)** 4.8 (8.2)
Social interaction 14.0 (23.5)** 4.0 (8.4)
Employment 12.4 (18.8)** 7.3 (20.0)
Physical dimension 2.6 (4.4) 2.2 (5.4)
Psychosocial dimension 11.7 (18.6)** 3.5 (7.2)
Total SIP score 8.0 (9.7)** 3.4 (5.6)
Data are expressed as mean, and sd  in parenthesis. The score 
are on a scale ranging 0-100. **: p<0.01, sarcoidosis patients 
versus controls (Student's t-test).
Table 3. -  Lung, respiratory and peripheral muscle 




IVC % pred 99 (11) 105 (12)
FEVl L 3.1 (0.9) 3.6 (0.7)
FEVl % pred 92 (10)** 106 (12)
7L,co % pred 86 (9) 100 (8)
TL,co normal/decreased 17/1 18/0
Pi,max (at RV) cmH20 -86.8 (28.7)** -112.8 (24.8)
% pred 96 (27)** 130 (28)
PE.max (at TLC) cmH20 91.6 (31.5)** 126.1 (34.8)
% pred 74 (19)** 107 (20)
Respiratory muscle
Endurance test completed n 12 17
Endurance time s 756 (246)** 869 (130)
Quadriceps force kgf
Male 43.1 (14.1) 45.4 (9.1)
Female 25.6 (8.4) 32.5 (4.8)
Hand muscle force kgf
Male 48.5 (12.8) 52.1 (8.6)
Female 23.1 (6.8) 33.5 (5.4)
Data are expressed as absolute number or mean, and sd  in 
parenthesis. IVC: inspiratory vital capacity; % pred: percentage 
of predicted value; FEVt: forced expiratory volume in one 
second; TL.CO: transfer factor of the lung for carbon monox­
ide; Pi,max: maximal inspiratory mouth pressure; RV: residual 
volume; PE.max: maximal expiratory mouth pressure; TLC: 
total lung capacity. **: p<0.01, sarcoidosis patients versus 
controls (Student's t-test).
the patients with sarcoidosis, the subscores were signi­
ficantly higher in the subscales "alertness behaviour", 
"home management", ’’recreation and pastimes", "sleep 
and rest", ’’social interaction" and "employment" (table 
2>‘Only one of the 18 patients had a slightly decreased 
7L,CO. The absolute values for FEVi as well as FEVl 
% pred were within the normal range for all patients, 
as also were the VC and TLC. However, FEVl % pred 
was lower in the patients than in the control subjects
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Table 4. -  Univariate regression analyses between 
Sickness Impact Profile (SIP) scores of patients with sar­
coidosis and respiratory muscle strengh, endurance time 





r -0.02 -0.28 -0.56 0.12 0.10
p-value ns NS <0.01 NS NS
Body care and movement
r -0.30 -0.07 -0.79 0.17 0.22
p-value ns NS <0.001 NS NS
HMF: hand muscle force; QF: quadriceps force; n s : non­
significant. For further definitions see legend to table 3.
(p<0.05). .Pi,max, PE,max, and respiratory muscle endu­
rance time were all lower in the sarcoidosis patients 
compared to the control subjects (p<0.05). Only one of 
the control subjects failed to complete the respiratory 
muscle endurance test for the 15 min period, whereas 
six of the 18 sarcoidosis patients did not finish the test 
(p<0.05). No differences were found in the respiratory 
muscle strength and endurance time between sarcoido­
sis patients who were treated with prednisone and those 
who were not.
Peripheral muscle strength, ue, quadriceps and hand 
muscle force, showed no differences between the sar­
coidosis patients and control subjects (table 3).
The respiratory muscle endurance time correlated with 
the SIP subscales "mobility” (p<0.01) and "body care and 
movement" (pcO.OOl). However, no correlations were 
found between the SIP scores and Pi,max, PE,max and 
peripheral muscle strength, respectively (table 4). Pati­
ents with symptoms (n=7) (table 1) showed lower Pl,max 
(p<0.03) and respiratory muscle endurance time (p<0.005), 
while patients who experienced fatigue (n=6) had a low­
er PE,max (p<0.03) compared to those without com­
plaints.
The radiographic stage was related to the SIP sub­
scales "alertness behaviour" (p<0.001), "emotional be­
haviour" (pcO.OOl), "home management" (p<0.005) and 
"social interaction" (pcO.OOl). The duration of disease, 
the FEVl, and the sACE levels showed no relationship 
with percentile scores of any of the subscales. Further­
more, no relationship between radiographic stage, sACE, 
respiratory muscle strength, and respiratory muscle 
endurance time were found.
Discussion
This study has shown that respiratory muscle stren­
gth and respiratory muscle endurance are reduced in 
patients with sarcoidosis. Patients with the symptom of 
fatigue had significantly lower maximum expiratory 
pressures than those without symptoms. A decreased 
respiratory muscle endurance time suggests the pres­
ence of respiratory muscle fatigue. Muscle fatigue has 
been defined as a condition in which there is a reduc­
tion in the capacity for developing force and/or veloc­
ity of a muscle in response to a load, and is reversible 
by rest [23]. In general, muscle fatigue occurs when­
ever energy demand exceeds energy supply [24]. Applying 
this to respiratory muscles, fatigue occurs when these 
muscles work under conditions where there is an imbal­
ance between energy demand and supply [24].
Muscle weakness is a condition in which the capac­
ity for a rested muscle to generate force is decreased [23]. 
In our patient group, we found decreased Pi,max and 
PE,max, which indicates inspiratory as well as expira­
tory muscle weakness. Previously, reduced respiratory 
muscle strength in sarcoidosis was reported by B a y d u r  
et a l  [13], who compared untreated patients suffering 
from sarcoidosis with control subjects, and found a de­
crease in maximal mouth pressures (Pi,max) in the sarcoi­
dosis patients. In agreement with this, B adr  and S harm a  
[14] found respiratory muscle dysfunction in 61% of a 
group of sarcoidosis patients. Moreover, in their study, 
the PE,max was significantly lower than in normal con­
trols [14].
The results of the present and previous studies, there­
fore, suggest that Pi,max and Pe,max are related to func­
tional impairment due to sarcoidosis. These results also 
emphasize the need for an integrative approach in the 
assessment and therapeutic management of sarcoidosis. 
It should be noted, however, that the respiratory mus­
cle tests applied in the present study depend on the co­
operation of the patient. To the best of our knowledge, 
nonvolitional tests of respiratory muscle function, such 
as magnetic or electrical stimulation of the phrenic ner­
ves, have not been reported in these patients.
Inspiratory muscles are the major muscle groups used 
in supporting the ventilatory demands of exercise, and 
the effort required to drive the inspiratory muscles dur­
ing exercise is a major contributor to the sensation of 
exertional dyspnoea [25]. With weak muscles, greater 
utilization of the available muscle mass is required to 
maintain a given external power output, resulting in an 
increased sense of effort. As a consequence, in persons 
with weak respiratory muscles, intolerable exertional 
discomfort and exertional dyspnoea occur at lower power 
outputs than in those with strong muscles [25]. In the 
present study, patients with symptoms had a decreased 
inspiratory muscle strength and endurance time, when 
compared to those without symptoms. The complaint of 
"fatigue" was associated with a lower expiratory mus­
cle strength. Moreover, a relationship was found bet­
ween the Pi,max and respiratory muscle endurance time. 
Thus, reduced respiratory muscle strength in the pres­
ence of sarcoidosis may contribute to exercise intoler­
ance independent of impairment in ventilatory function. 
This conclusion is consistent with that of H a m ilto n  
et a l  [25], who showed that in patients with cardio­
respiratory disorders, respiratory, as well as peripheral, 
muscle strength was a significant contributor to symp­
tom intensity and work capacity, in addition to any con­
tribution from ventilatory, gas exchange, and circulatory 
impairment.
Several factors, such as hypoxaemia, hypercapnia, 
malnutrition, decreased blood supply to the muscles, 
drugs, and electrolyte abnormalities, contribute to res­
piratory muscle weakness and fatigue, e.g. in chronic 
obstructive pulmonary disease patients [26, 27]; how­
ever, these are unlikely to contribute in sarcoidosis. Which 
factor or combination of factors is responsible for this 
effect in sarcoidosis has not yet been established. In the 
absence of metabolic abnormalities, recent data have 
emphasized the role of inflammatory products on diff­
erent aspects of muscle metabolism. As in other immune- 
mediated disorders, most clinical manifestations of
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sarcoidosis are secondary to the direct effect of the ac­
cumulation of activated immunocompetent cells in the 
involved tissues, notably helper T-lymphocytes and mac­
rophages, and by an increased production of different 
cytokines [28, 29]. These cytokines appear to be pro­
duced in inflamed lesions of sarcoidosis and released 
into the bloodstream [30]. Future identification of these 
products could lead to specific therapeutic interventions 
aimed at blocking their effect in the clinical manage­
ment of patients with inflammatory disorders, such as 
sarcoidosis.
As previously suggested, impaired respiratory muscle 
function suggests that the respiratory muscles can be 
involved in the granulomatous process of sarcoidosis [13]. 
Many reports have described granulomatous myopathy 
without overt manifestations of sarcoidosis elsewhere; 
sometimes a past history of sarcoidosis was suggested. 
Hence, granulomas in muscles may persist after those 
in other organs have become inactive or have resolved 
in patients who have passed through the active gener­
alized stages of sarcoidosis without obvious symptoms
[31]. Little is known about involvement of respiratory 
muscles, as only a few cases have been described [14,
32, 33], For example, it is not known whether diap­
hragm and/or intercostal muscle involvement in sar­
coidosis is a possible contributory factor to dyspnoea or 
impairment of vital capacity [31]. However, histologi­
cal confirmation of respiratory muscle involvement is 
hard to obtain. Furthermore, myopathy, including disor­
ders of the respiratory muscles, is a well-known side- 
effect of corticosteroids [34, 35], It should be considered 
especially with higher doses of steroids, in the presence 
of markedly impaired respiratory muscle strength or con­
tinuous treatment with fiuorinated steroids [36]. In the 
present group of patients, only seven had been treated 
with steroids during the 3 months prior to the study and 
the doses they received were low. Moreover, the respi­
ratory and peripheral muscle strength did not differ 
between patients with or without a history of corticos­
teroid treatment.
The TL.CO is considered by some authors to be the 
most sensitive index of lung function in sarcoidosis. It 
is often the first or only index to be decreased [14]. 
Remarkably, however, in the present study the respi­
ratory muscle force and endurance were significantly 
lower than in the control group, even though other lung 
function tests were normal. This suggests that maximal 
mouth pressure and respiratory muscle endurance time 
may be more sensitive to functional impairment due to 
sarcoidosis than are the 7lL,CO or VC, which have been 
suggested as the best indices to correlate with working 
capacity [37]. The relationship between radiographic 
stage, lung function and exercise abnormality have, how­
ever, been variable [38]. Clearly, there is a wide spectrum 
of tissue inflammation and organ dysfunction within, as 
well as between, each radiographic stage. K a r e t z k y  and 
M c D o n o u g h  [38] found that the magnitude of func­
tional impairment may vary widely from the apparent 
histopathological involvement as reflected by chest 
radiography and lung volumes. In the present study, we 
found a relationship between the radiographic stage and 
impairment in the fields "alertness behaviour", "emo­
tional behaviour", "home management" and "social inter­
action".
Furthermore, in the present study, the SIP subscales 
"mobility" and "body care and movement" as well as the 
presence of symptoms were shown to correlate with res­
piratory muscle endurance time. However, for both of 
these latter domains there was no difference between 
patients and the control subjects. Moreover, our results 
show that patients with sarcoidosis are limited in phy­
sical and psychosocial functioning. They appear to be 
particularly affected in the fields "sleep and rest", "re­
creation and pastime", "employment", "alertness beha­
viour", "home management" and "social interaction", 
compared to a control group [15]. This diversity illustra­
tes the broad impact of sarcoidosis on patients' quality 
of life.
In conclusion, respiratory muscle strength and endu­
rance are reduced in patients with sarcoidosis. Decreas­
ed respiratory muscle endurance was found to be related 
particularly to the Sickness Impact Profile subscales 
"mobility" and "body care and movement". However, no 
such relationship was found between these latter Sick­
ness Impact Profile subscales and routinely performed 
lung function tests, such as transfer factor and spirom­
etry. Measuring respiratory muscle function seems to 
quantify and characterize the functional impairment in 
patients with sarcoidosis and reflects symptoms, such 
as fatigue and general weakness, that are otherwise dif­
ficult to assess objectively. Therefore, we suggest that 
measurements of respiratory muscle strength and endu­
rance time could be usefully included in the diagnostic 
work-up and follow-up of patients with sarcoidosis. Fur­
ther studies are needed to assess respiratory and peri­
pheral muscle involvement, as well as the relationship 
with the presence of inflammatory characteristics in sar­
coidosis.
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